To determine whether wt-IDH2 could be a potential therapeutic target in AML cells, we next used IDH2 inhibitor AGI-6780, a chemical compound known to potently inhibit both mutant and wild-type IDH2 [36], to treat U937 and ML-1 cell lines with wt-IDH2 and evaluated its impact on cell viability and proliferation. Here, IDH2 is linked to acute myeloid leukemia.